Q-omics provides the consensus-scored IL17A profile across patient tissues and cancer cell-line models. IL17A expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IL17A is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, IL17A RNA expression shows 5,829 significant pathway-activity associations, with the highest sampling consensus in PRAD. Together, these results highlight SKCM, HNSC, and PRAD as cancer lineages where IL17A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL17A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL17A survival associations across molecular data types. IL17A RNA expression shows survival associations in the most cancer types (18), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL17A RNA expression–survival associations across cancer types. High IL17A expression shows unfavorable associations in SKCM, ACC, DLBC and UCS, but favorable associations in HNSC and OV. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IL17A RNA expression.
This table summarizes IL17A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IL17A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL17A shows lower tumor expression in HNSC, THCA and STAD and higher tumor expression in COAD, LUAD and LIHC. The HNSC box plot shows higher IL17A RNA expression in normal versus tumor tissue (log2 FC = −0.272, t-test p = .007).
This table shows molecular features associated with IL17A in patient tissues and cancer cell lines. In patient samples, IL17A shows the broadest associations at the RNA and protein expression levels, with PRAD recurring as the lineage with the largest associated feature set. In cancer cell lines, IL17A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_NSCLC_LUAD.
